Incorporated in 1976, Lyka Labs Ltd is a WHO-GMP certified and ISO 9001-certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients (APIs) across various therapeutic segments. The company specializes in Lyophilized injections, topical formulations (cream, ointment, foams, gels & lotions), and is primarily engaged in formulation and manufacturing lyophilized products. Lyka Labs Limited operates with its Corporate Office and R&D Centre in Mumbai, and has manufacturing facilities located in Ankleshwar, Gujarat and Tarapur, Maharashtra. The company's dedicated Lyophilization facility is situated in Ankleshwar. The Chairman of the company is Babulal Jain, and the Managing Director is Kunal N Gandhi.
Lyka manufactures a wide array of dosage forms, including Tablets, Capsules, External Preparations, Dry Powder Injections, Lyophilized Injections, and APIs. The company's core competency lies in Lyophilization, where it produces 22 finished formulations and 10 Sterile APIs.
The company's product range encompasses antibiotics, topical steroids for skin disorders, oncology products, cardio-vascular drugs, and anti-inflammatory agents. It offers various formulations such as emollients, anti-aging products, cleansing lotions, hair care products, anti-dandruff shampoos, sunscreens, anti-acne treatments, antioxidant tablets and combinations, proton pump inhibitors, anti-fungal, anti-malarial, anti-bacterial agents, corticosteroid hormones, and cephalosporins. Lyka Labs also manufactures a diverse range of Ayurvedic and animal health care products.
The company's prospects for lyophilized products extend to both formulations and Bulk Drugs, with a presence in both domestic and international markets. Lyka Labs' subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.
As of 20th May 2025, the market capitalization of Lyka Labs Ltd (LYKALABS) stands at ₹430.17 Cr. The company has demonstrated an upward trend in its financial performance over recent quarters. For the quarter ended December 2024, net profit rose by 52.25% to ₹2.71 crore, compared to ₹1.78 crore in the previous quarter ended December 2023.
The quarter ended September 2024 saw robust growth momentum, with net profit reported at ₹2.10 crore, a significant improvement from a net loss of ₹0.49 crore in the corresponding quarter of the previous year. Sales increased by 47.05% to ₹41.16 crore in Q3 FY2024-25, up from ₹27.99 crore in Q3 FY2023-24.
Key Financial Metrics:
• TTM Profit After Tax: ₹8 Cr
• EPS (Dec 2024 Quarter): 0.75
• EPS (FY 2023-24): -0.79
• Dividend Declared (FY 2024): ₹0.0 per share
Lyka Labs Ltd (LYKALABS) operates within the Healthcare sector, specifically the Pharmaceuticals sub-sector. Classified as a Small Cap company by Value Research, Lyka Labs has shown revenue growth at a yearly rate of 9.1% over the last 5 years, closely matching the industry average of 9.04%. Its market share has remained stable at 0.03% during this period.
Current valuation metrics include a 52-week high of ₹176.59 and a 52-week low of ₹96.80. As of 08-Jul-2025, the company's P/B ratio is 3.79 times, which represents a 2% discount to its peers' median range of 3.85 times. However, its P/E ratio stands at 49.00 times as of the same date, reflecting a 15% premium compared to its peers' median range of 42.56 times.
Promoter holding in Lyka Labs Ltd has seen a slight increase to 58.16% as of March 2025, up from 58.10% as of June 2024. There is no reported pledging of promoter shares. The company actively engages with stakeholders through regular board meetings and corporate announcements.
Notable upcoming events include the NCLT hearing for Lyka Labs' merger, which has been adjourned to 10th July 2025. Furthermore, Lyka Labs has entered into an agreement to be acquired by Ipca Laboratories. The company remains focused on innovation and quality manufacturing, committed to generating shareholder value through its specialized pharmaceutical manufacturing capabilities and a diverse product portfolio across various therapeutic segments.
